Harnessing ecology to deliver
novel, cultured microbial therapies​

BiomeBank is a clinical stage biotechnology company with a mission to treat and prevent disease by restoring gut microbial ecology.
Introducing BiomeBank (1:40)

A unique ecosystem based approach to drug development

Like many thriving ecosystems found in nature, diversity is the key ingredient for a healthy gut microbiota. Modern lifestyles and environments are causing gut bacterial diversity to decline, and this is associated with the rise of numerous chronic diseases.


BiomeBank is at the forefront of developing therapies that treat disease through restoration of our gut microbial ecosystem.

Consortiome™:
a breakthrough technology

Our team of translational microbiome experts have developed a breakthrough co-culturing platform that has enabled us to generate an artificial human gut microbial community in a bioreactor – the Consortiome™.

Consortiome™ is a rationally designed consortia containing more than 90% of the known gene families in a healthy person’s microbiome

The Consortiome™ platform enables the development of bespoke therapies with targeted functions to treat disease at a much lower cost than other microbial products.

The Consortiome Explained (2:00)

Track-record in
commercialisation​

BiomeBank has strong track record of commercialisation. Our donor-derived microbiome therapy was the first regulator-approved microbial therapy in the world. We are currently supplying this product to physicians to treat Australian patients with Clostridioides difficile infection.

Optimising
the Drug Discovery Funnel

1.

IDENTIFY
Leveraging real-world, human data from our existing therapies to establish the causation of disease, our ‘human-first’ model of discovery allows us to more rapidly and precisely identify the ‘mechanism of action’ when compared to animal models.

2.

DEVELOP
Harnessing the latest technology, we mine the real-world data and select candidate strains from our leading culture collection. Employing our cutting-edge ConsortiomeTM platform we engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties that manifest at the community level.

3.

OPTIMISE
Delivering BiomeBank potential drug candidates with the highest chance of clinical success.

We are a multidisciplinary team of research scientists and drug development experts who are at the forefront of microbiome research, looking to discover and develop microbiome-based therapies.

The translation of research into the development of innovative and life-saving microbiome-based therapies are further bolstered by BiomeBank’s partnership with world-leading biomedical research organisations. This includes RMIT University, Hudson Institute of Medical Research, and Hospital Networks globally.

Our New Facility (2:20)

BiomeBank's pioneering research has been published in these leading medical journals:

I want to know more

I'm an investor

I want to learn more about BiomeBank and its microbiome drug development portfolio.

I'm a clinician

I want to know how microbiome-based therapies can help my patients.

BiomeBank was recently featured on the award winning show Viewpoint with Dennis Quaid. The segment was screened on Fox Business and Public Television Stations across the USA.

Watch the segment on the Viewpoint website here.